Compare

Becton Dickinson/$BDX

1D1W1M3M6MYTD1Y5YMAX

About Becton Dickinson

Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Ticker
$BDX
Sector
Health
Primary listing
NYSE
Employees
72,000
Headquarters
Franklin Lakes, United States
Website
www.bd.com

Becton Dickinson Metrics

BasicAdvanced
$53B
58.17
$3.33
0.28
$4.20
2.17%

What the Analysts think about Becton Dickinson

Analyst ratings (Buy, Hold, Sell) for Becton Dickinson stock.
Analyst projections of the future price of Becton Dickinson stock.

Bulls say / Bears say

BD’s continuing-operations revenue rose 4.4% on a currency-neutral basis in Q3. Management raised the midpoint of adjusted EPS guidance and expects revenue growth near the top of its range. (Becton, Dickinson and Company)
BioPharma Systems grew 5.2% on a currency-neutral basis, with double-digit growth in biologics led by GLP-1 demand. Management also cited about 100 agreements across its biologics pipeline. (The Motley Fool)
Year-to-date cash from continuing operations rose 33.3% to $2.1 billion and free cash flow rose 44.6% to $1.7 billion. That stronger cash generation gives BD more capacity to fund investment and reduce debt. (Becton, Dickinson and Company)
Management expects low-single-digit revenue growth in fiscal 2027, with Alaris comparisons creating a 200-basis-point headwind as the temporary pump replacement cycle rolls off. (The Motley Fool)
BD’s SEC filing says FDA findings at its El Paso site could require further corrective action and product recalls. If deficiencies remain unresolved, the FDA could take additional action and restrict approvals tied to the facility. (U.S. Securities and Exchange Commission)
BD recalled certain lots of intraosseous needle sets after reports that the obturator could remain stuck after insertion. By June, it had received 75 complaints and 45 serious-injury reports, raising product-safety and liability risks. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.

Becton Dickinson Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Becton Dickinson Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Becton Dickinson News

AllArticlesVideos

Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing

Reuters2 weeks ago

Becton, Dickinson and Company Q3 Earnings Call Highlights

MarketBeat2 months ago

Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access

Reuters3 months ago

Funds containing Becton Dickinson

AllUSDEURGBP
Funds
Fund name
Fund size
$BDX weighting
SPDR S&P US Dividend Aristocrats€SPYD
$3.8B1.53%
SPDR S&P US Dividend Aristocrats£USDV
$3.8B1.53%
iShares AI Adopters and Applications€AIAA
€169M1.00%
iShares AI Adopters and Applications£AIAA
£145M1.00%
iShares S&P 500 Health Care Sector€IUHE
€125M0.82%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.